Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products

L’Oréal announced today it is recalling all lots of its acne treatment Effaclar Duo in the US due to concerns over benzene contamination.¹ The product, sold under the La Roche-Posay brand, contains benzoyl peroxide (BPO).

Christopher Bunick, MD, PhD, associate professor of dermatology and physician-scientist at Yale School of Medicine in New Haven, Connecticut, and editor in chief of Dermatology Times, discussed the news just announced today live at the 2025 American Academy of Dermatology Annual Meeting

Bunick’s key message to clinicians is that recalls stem from findings that benzoyl peroxide can degrade into benzene, a known carcinogen. While the full extent of health risks remains unclear and no direct causative link has been established, the recalls highlight a need for greater formulation stability in benzoyl peroxide products.

Key points for clinicians:

• Patient Safety First: Companies are acting responsibly by recalling affected products while further research is conducted.
• Stability Concerns: The degradation of benzoyl peroxide into benzene demonstrates the need for improved formulations.
• Ongoing Research: More data is needed to determine the true health impact of benzene exposure from these products.

For now, reassure patients that these recalls do not indicate an immediate health crisis but rather a precautionary step. Encourage alternative acne treatments as needed while clinicians await further guidance.

Reference

1. Edney A. L’Oreal recalls acne treatment on cancer-linked chemical. Bloomberg Law. March 10, 2025. Accessed March 10, 2025. https://news.bloomberglaw.com/health-law-and-business/loreal-recalls-acne-treatment-in-us-on-cancer-linked-benzene